September 30, 2019
Adlai Nortye’s study of oral EP4 antagonist shows encouraging clinical results in locally advanced rectal cancer
Researchers presented results from Adlai Nortye’s investigational, potentially first in class oral EP4 antagonist, two dose levels of AN0025 in combination with the standard of care for locally advanced rectal cancer where primary resection without chemoradiotherapy is unlikely to achieve clear margins as defined by MRI at ESMO.